Inactive Instrument
Five Prime Therapeutics, Inc. Stock
Stocks
FPRX
US33830X1046
Biotechnology & Medical Research
| 1 day | +0.03% |
| Manager | Title | Age | Since |
|---|---|---|---|
James Bradner
CEO | Chief Executive Officer | 53 | - |
Peter Griffith
DFI | Director of Finance/CFO | 67 | - |
Jonathan Graham
LAW | General Counsel | 65 | - |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 16/04/21 | Issuer sale | Director | 45,000 | 0.0966% | ||
| 16/04/21 | Issuer sale | Director | 46,250 | 0.0993% | ||
| 16/04/21 | Issuer sale | Director | 60,000 | 0.1288% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.03% | +0.16% | - | - | 1.74B | |
| +3.31% | +1.93% | +69.29% | +129.27% | 55.78B | |
| -1.32% | +16.55% | +89.14% | +101.41% | 55.66B | |
| -1.28% | +3.17% | -12.81% | -13.04% | 23.84B | |
| +1.79% | +8.13% | +7.17% | +424.70% | 22.7B | |
| +4.45% | +8.43% | +37.08% | -29.19% | 16.12B | |
| +0.24% | +5.96% | +24.59% | +186.97% | 13.64B | |
| +5.51% | +22.37% | +171.85% | +333.54% | 14.8B | |
| +1.83% | +4.69% | +78.54% | +143.84% | 12.16B | |
| -2.37% | +7.60% | +156.91% | +160.12% | 11.85B | |
| Average | +1.22% | +6.15% | +69.08% | +159.74% | 25.17B | |
| Weighted average by Cap. | +1.19% | +5.02% | +66.10% | +144.99% |
Employees
51
